专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明公开

EP2147978A2 N-Terminally truncated HER-2/NEU protein as a cancer prognostic indicator 审中-公开
标题翻译： N端截短的HER-2 / neu蛋白作为癌症预后指标
公开(公告)号：EP2147978A2
公开(公告)日：2010-01-27
申请号：EP09166038.1
申请日：1999-11-13
申请人： OREGON HEALTH SCIENCES UNIVERSITY
发明人： Clinton, Gail M.
IPC分类号： C12Q1/00 , G01N33/53 , G01N33/567 , G01N33/574 , A61K31/198 , A61P35/00
CPC分类号： G01N33/57484 , G01N2800/50 , G01N2800/52
摘要： There is disclosed an initial identification of an N-terminally truncated HER-2/neu product.
This product is a 95kDa polypeptide having in vitro kinase activity (as determined by western blotting). Moreover, immunoprecipitations using domain specific antibodies was able to utilize this specific polypeptide from intracellular fragments as a diagnostic and prognostic indicator of adenomacarcinomas without the severe dilution effects encountered by measuring ECD.

62. 发明公开

EP1892252A2 Intermediate conductance, calcium-activated potassium channels and uses thereof 失效
标题翻译：电脑软件卡尔卡卡纳尔电脑软件公司Konduktanz und Verwendungen davon
公开(公告)号：EP1892252A2
公开(公告)日：2008-02-27
申请号：EP07012908.5
申请日：1997-09-10
申请人： OREGON HEALTH SCIENCES UNIVERSITY , Ica-gen, Inc.
发明人： Adelman, John P. , Silvia, Christopher P. , Maylie, James , Bond, Chris T.
IPC分类号： C07K14/705
CPC分类号： C07K14/705
摘要： This invention relates to intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and method for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
摘要翻译：本发明涉及中间电导，钙激活的钾通道蛋白。更具体地，本发明涉及用于制备和检测钙激活的钾通道蛋白质和编码钙激活的钾通道蛋白质的核酸的组合物和方法。本发明还提供了用于测定通过钙激活钾通道增加或减少钾离子通量的化合物的方法和组合物。

63. 发明公开

EP1287033A2 PT32 SPERM PROTEIN, SPERM C-YES, OOCYTE CYTOPLASMIC C-YES, AND USES THEREOF 审中-公开
标题翻译：精子蛋白PT32与这种蛋白质的用途
公开(公告)号：EP1287033A2
公开(公告)日：2003-03-05
申请号：EP01935878.7
申请日：2001-05-25
申请人： QUEEN'S UNIVERSITY AT KINGSTON , OREGON HEALTH SCIENCES UNIVERSITY
发明人： OKO, Richard , SUTOVSKY, Peter
IPC分类号： C07K14/705
CPC分类号： C07K14/47 , A01K2217/075 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K2319/00
摘要： The perinuclear theca 32 (PT32) protein is disclosed and shown to interact with tyrosine kinase c-Yes. PT32, c-Yes, fragments thereof, and molecules that bind thereto can be used in methods of enhancing fertility, treating or diagnosing diminished fertility and abnormal spermiogenesis, in providing contraception, and in identifying contraceptive and fertility-enhancing agents. Transgenic, non-human animals also are disclosed.

64. 发明公开

EP1257822A1 HER-2 BINDING ANTAGONISTS 有权
标题翻译： HER-2结合拮抗剂
公开(公告)号：EP1257822A1
公开(公告)日：2002-11-20
申请号：EP01912833.9
申请日：2001-02-16
申请人： OREGON HEALTH SCIENCES UNIVERSITY
发明人： CLINTON, Gail , HENNER, William, D. , EVANS, Adam
IPC分类号： G01N33/567 , G01N33/574 , C07K16/00
CPC分类号： C07K16/32 , Y10T436/143333
摘要： There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2 or SEQ ID NO:13, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier. Also disclosed are prognostic and diagnostic assays.

65. 发明公开

EP1226279A1 MODULATION OF NEUROENDOCRINE DIFFERENTIATION BY PROTEIN 25.1 有权
标题翻译： NEUROKRINEN分化的调节由蛋白25.1
公开(公告)号：EP1226279A1
公开(公告)日：2002-07-31
申请号：EP00975512.5
申请日：2000-10-30
申请人： OREGON HEALTH SCIENCES UNIVERSITY
发明人： WILSON, Elizabeth , ROSENFELD, Ron, G. , OH, Youngman
IPC分类号： C12Q1/68 , G01N33/53 , A61K39/395 , C12N15/11 , C07H21/04
CPC分类号： C07K14/4702 , A61K38/00 , C07K2319/00
摘要： There is disclosed drug candidate screening assays, diagnostic assays, and therapeutic methods for tumor suppression and the treatment of cancer, including modulating induction of neuroendocrine differentiation in cancer cells, utilizing a novel IGFBP-rP1 interacting protein called P25.1 as the intervention target. The present invention further provides a P25.1 cDNA sequence, a P25.1 polypeptide and fragments thereof, an anti-P25.1 antibody, and anti-25.1 antisense oligonucleotides.

66. 发明公开

EP1194165A1 TAGGED EPITOPE PROTEIN TRANSPOSABLE ELEMENT 审中-公开
标题翻译：转座元件，表位标记的蛋白ENCODED
公开(公告)号：EP1194165A1
公开(公告)日：2002-04-10
申请号：EP00937880.3
申请日：2000-05-26
申请人： Oregon Health Sciences University
发明人： HEFFRON, Fred, L. , PARKER, David, C. , ELLEFSON, Dolph, D.
IPC分类号： A61K39/04 , A61K39/112 , A61K39/12 , A61K39/02
CPC分类号： C07K14/70539 , A61K39/0011 , A61K39/12 , A61K39/21 , C12N15/1034 , C12N15/63 , C12N2740/16034 , C12Q1/689 , Y02A50/412
摘要： A transposable element is provided that as a 3' and a 5' end. The transposable element includes a 5' recombining site 5' of a nucleic acid sequence encoding a selectable marker, a 3' recombining site 3' of the nucleic acid sequence encoding a selectable marker, a nucleic acid sequence encoding and MHC epitope 5' to the 5' recombining site or 3' to the 3' recombining site, and an insertion end comprising an inverted repeat sequence sufficient for integration of the transposable element at the 5' and the 3' end of the transposable element. In one embodiment, a transposable element is provided that has a 5' and a 3' end. The transposable element includes a 5' loxP sequence 5' of a nucleic acid encoding a selectable marker, a 3' loxP sequences 3' of a nucleic acid encoding the selectable marker, an MHC epitope 5' to the 5' loxP sequences or 3' of the 3' loxP sequence, an insertion end at the 5' end of the transposable element, and an insertion end at the 3' of the transposable element. A method is provided for detecting an antigenic epitope of a pathogen by infecting a pathogenic cell with a transposable element of the invention, wherein the infection results in the integration of the transposable element in a nucleic acid sequence of the bacterial cell; transforming the pathogenic cell with a vector comprising a transposase; contacting a eukaryotic cell that can internalize the pathogenic cell with the pathogenic cell infected with the transposable element; contacting the eukaryotic cell with a specific binding partner that recognizes the MHC epitope; identifying the labeled eukaryotic cells and externalizing the bacteria cell. The externalized bacterial cell may be grown to produce a population of bacterial cells, and the nucleic acid sequence of the bacterial cell that has the integrated transposable element is identified. This nucleic acid sequence encodes the antigenic element of the panthogen. A method is also provided for generating a carrier vaccine by infecting a bacterial cell with the transposable element of the invention, wherein the transposable further comprises an antigen associated with a disease operably linked to the MHC epitope of the transposable element. The infection of the bacteria results in the integration of the transposable element in a nucleic acid sequence of the bacterial cell. The pathogenic cell is then internalized into a eukaryotic cell and the eukaryotic cell is exposed to a specific bindind agent that recognizes the MHC epitope, identifying labeled eukaryotic cells are identified and lysed to externalize the bacteria cell, which is cultured to produce a population of bacterial cells. The nucleic acid sequence of the bacterial cell that has the integrated transposable element is identified, wherein the nucleic acid sequence encodes the antigenic element of the pathogen. The graving bacterial cell identified, and may be used as the carrier vaccine.

67. 发明公开

EP1053002A1 TREATMENT OF BONY DEFECTS WITH OSTEOBLAST PRECURSOR CELLS 审中-公开
标题翻译：治疗骨缺损骨原细胞
公开(公告)号：EP1053002A1
公开(公告)日：2000-11-22
申请号：EP99906914.9
申请日：1999-02-10
申请人： OREGON HEALTH SCIENCES UNIVERSITY
发明人： HOLLINGER, Jeffrey, O. , WINN, Shelley, R. , FRANK, Edmund , WONG, Shou, C.
IPC分类号： A61K38/00 , A61K38/19 , A61K48/00 , A61B17/56 , C07K14/51 , A61F2/28
CPC分类号： C12N5/0654 , A61B1/00082 , A61B1/00154 , A61B1/0051 , A61F2/2803 , A61F2/44 , A61F2/4601 , A61F2002/2817 , A61F2002/2839 , A61F2002/30062 , A61F2002/3028 , A61F2002/30298 , A61F2002/307 , A61F2002/30703 , A61F2002/4635 , A61F2210/0004 , A61F2230/0063 , A61F2230/0091 , A61F2250/0081 , A61K38/1875 , A61K48/00 , A61L27/26 , A61L27/3821 , A61L27/3847 , A61L27/44 , A61L2430/02 , C08L67/04 , C08L89/06
摘要： Healing of bony defects is promoted by suspending osteoblast precursor cells (OPCs) in a porous matrix, which is implanted in the bony defects. The OPCs may be transformed to express a bone morphogenetic protein (BMP), such as BMP-2. Devices are also disclosed for introducing the OPCs into bony defects. One device is a cannula (100) having concentric passageways, such that an endoscope (122) can be introduced through one of the passageways, while the OPCs are introduced through the endoscope or through another passageway without increasing pressure on the OPCs to such an extent that the cells are damaged. A cartridge unit (126) can be inserted through an endoscope to gently advance a cellular suspension through a catheter into the bone.

68. 发明公开

EP0944399A2 COVALENT POLAR LIPID CONJUGATES FOR TARGETING 失效
标题翻译：靶向共价极性脂质KONJUKATE
公开(公告)号：EP0944399A2
公开(公告)日：1999-09-29
申请号：EP97913811.0
申请日：1997-10-27
申请人： OREGON HEALTH SCIENCES UNIVERSITY , Yatvin, Milton B. , Stowell, Michael H., B. , Meredith, Michael J.
发明人： YATVIN, Milton, B. , STOWELL, Michael, H., B. , MEREDITH, Michael, J.
IPC分类号： A61K47 , A61K31 , A61P25 , A61P43 , C07H19
CPC分类号： C07H19/06 , A61K31/00 , A61K47/543 , A61K47/544 , B82Y5/00 , C07H19/10
摘要： This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmicokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic and neurological drugs, agents and compounds, for rapid and efficient introduction of such agents across the blood-brain barrier. Further, the invention provides means for retention and prolonged enzymatic release of psychotropic, neurotropic and neurological drugs, agents and compounds comprising the conjugates of the invention, in the brain and central nervous system.

69. 发明公开

EP0915976A2 METHOD TO IDENTIFY COMPOUNDS FOR DISRUPTING PROTEIN/PROTEIN INTERACTIONS 失效
标题翻译：方法用于鉴定蛋白/蛋白相互作用阻止
公开(公告)号：EP0915976A2
公开(公告)日：1999-05-19
申请号：EP97944479.0
申请日：1997-09-26
申请人： ICOS CORPORATION , OREGON HEALTH SCIENCES UNIVERSITY
发明人： HOEKSTRA, Merl F. , GOODMAN, Richard H.
IPC分类号： C12N15 , C12Q1
CPC分类号： C12N15/635 , C12N15/1055 , C12N15/81 , C12Q1/6897
摘要： The present invention relates generally to materials and methods for identification of inhibitors of interactions between known binding partner proteins.

70. 发明公开

EP0843726A1 OPIOID ANTAGONISTS AND METHODS OF THEIR USE 失效
标题翻译：安东尼·安德烈·安德鲁
公开(公告)号：EP0843726A1
公开(公告)日：1998-05-27
申请号：EP96928209.0
申请日：1996-08-12
申请人： OREGON HEALTH SCIENCES UNIVERSITY
发明人： GRISEL, Judith, E. , MOGIL, Jeffrey, S. , GRANDY, David, K. , BUNZOW, James, R. , CIVELLI, Olivier , REINSCHEID, Rainer, Klaus , NOTHACKER, Hans-Peter , MONSMA, Frederick, James
IPC分类号： C12N15 , A61K38 , A61K51 , A61P25 , A61P39 , C07K14 , C12N5
CPC分类号： C07K14/665 , A61K38/00
摘要： The present invention relates to a novel mammalian anti-opioid receptor protein (OFQR), peptide ligands (such as OFQ) that bind to OFQR, and methods of using the OFQ peptide and analogues to reverse the physiologic effects of opiates such as morphine. The isolation, characterization and pharmacological use of the endogenous peptide ligand is described. A particular embodiment of the OFQ peptide is a heptadecapeptide having an FGGF aminoterminal motif. The peptide specifically binds to an OFQ receptor protein heterologously expressed in mammalian cells. The peptide does not bind with high affinity to ν, δ or λ receptors, but it antagonizes opioid mediated effects (such as analgesia and hypothermia) without increasing nociceptive sensitivity. Tyrosine substitution variants of the peptide ligand specifically bind to the opioid receptor and can be radioiodinated. Also provided are methods of making such peptide ligands and OFQR antagonists, and methods of using the ligands for diagnostic and therapeutic uses and for the identification of other naturally-occurring or synthetic opioid receptor ligands.
摘要翻译：本发明涉及一种新型哺乳动物抗阿片类受体蛋白（OFQR），与OFQR结合的肽配体（如OFQ），以及使用OFQ肽和类似物逆转阿片剂如吗啡的生理作用的方法。描述了内源肽配体的分离，表征和药理学应用。 OFQ肽的具体实施方案是具有FGGF氨基末端基序的十七肽。该肽特异性结合在哺乳动物细胞中异源表达的OFQ受体蛋白。肽不能以高亲和力结合到mu，δ或κ受体，但它拮抗阿片样物质介导的作用（如镇痛和低体温），而不增加伤害敏感性。肽配体的酪氨酸取代变体特异性结合阿片受体并可以放射性碘化。还提供了制备这种肽配体和OFQR拮抗剂的方法，以及使用该配体进行诊断和治疗用途以及鉴定其它天然存在或合成的阿片受体配体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式